- Investing Ideas
- U.S. Pharmaceuticals & Biotech Blue chip stocks
U.S. Pharmaceuticals & Biotech Blue chip stocks
Results
18
18 companies
Charles River Laboratories International
Market Cap: US$10.9b
Charles River Laboratories International, Inc.
CRL
US$226.79
7D
21.5%
1Y
46.9%
ICON
Market Cap: US$13.3b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$173.71
7D
21.8%
1Y
16.7%
Axsome Therapeutics
Market Cap: US$12.4b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$244.77
7D
1.2%
1Y
137.7%
Elanco Animal Health
Market Cap: US$12.4b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.61
7D
6.2%
1Y
70.5%
Ionis Pharmaceuticals
Market Cap: US$13.3b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$79.29
7D
4.3%
1Y
98.5%
Natera
Market Cap: US$38.9b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$271.45
7D
4.4%
1Y
68.0%
Insmed
Market Cap: US$22.7b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$106.62
7D
4.4%
1Y
9.2%
BioMarin Pharmaceutical
Market Cap: US$11.1b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$57.22
7D
1.3%
1Y
1.8%
Madrigal Pharmaceuticals
Market Cap: US$12.2b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$536.95
7D
4.6%
1Y
78.9%
Viatris
Market Cap: US$18.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.88
7D
0.8%
1Y
73.0%
Alnylam Pharmaceuticals
Market Cap: US$39.2b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$301.03
7D
4.5%
1Y
-6.5%
Jazz Pharmaceuticals
Market Cap: US$14.9b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$240.97
7D
4.7%
1Y
120.2%
BeOne Medicines
Market Cap: US$32.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$284.97
7D
3.2%
1Y
16.2%
Royalty Pharma
Market Cap: US$32.9b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$56.07
7D
1.3%
1Y
56.3%
Merck
Market Cap: US$319.5b
Operates as a healthcare company worldwide.
MRK
US$128.50
7D
7.4%
1Y
57.1%
Neurocrine Biosciences
Market Cap: US$17.1b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$168.54
7D
4.4%
1Y
31.7%
Krystal Biotech
Market Cap: US$11.1b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$371.67
7D
9.2%
1Y
167.4%
Gilead Sciences
Market Cap: US$156.8b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$126.34
7D
1.0%
1Y
13.1%